Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

#RemoteDetailing

- PMLiVE

Merck and Ridgeback fulfil US deal for molnupiravir

Over three million courses of the investigational oral antiviral COVID-19 treatment have been supplied

- PMLiVE

HCA launches first CPD standards framework for healthcare professionals

The CPD Standards Framework has been produced by a board of pharmaceutical, healthcare and charity communications agencies

Protecting Ownership of Technological & Pharmaceutical Innovation

Joshua Goldberg, Co-Managing Partner at Nath, Goldberg & Meyer, discusses key intellectual property issues and pitfalls in the digital health space, the importance of international patent protection, and why it’s...

Impetus Digital

Measuring Vital Health Indicators Through Your Camera

Dr. Keith Thompson, CMO at Nuralogix, dives into virtual care, telemedicine, and advanced digital health tools for improving primary care workflows and population health. He also shares his insights into...

Impetus Digital

- PMLiVE

Merck’s Keytruda combined with chemotherapy could benefit thousands of breast cancer patients

The combination significantly reduces cancer recurrence by approximately 37% and reduces secondary breast cancer by 39%

EU flag

EMA establishes DARWIN EU Coordination Centre

The new centre will give the EMA and other EU member states access to reliable, real-world evidence for EU medicine assessments

LOOKING AHEAD: UNDERSTANDING THE NHS CUSTOMER’S PRIORITIES FOR 2022/23

The recently published operational planning guidance describes what the NHS needs to achieve this year. Wilmington Healthcare’s Oli Hudson explores some of its critical themes and what they mean for...

Wilmington Healthcare

Biogen Idec building

SMC approves Biogen’s Vumerity for patients with multiple sclerosis

The new, at-home oral treatment has been developed for adults in Scotland living with relapsing-remitting multiple sclerosis

- PMLiVE

FDA issues approval for Sanofi’s Enjaymo treatment for patients with CAD

The treatment is the first-of-its-kind for patients living with cold agglutinin disease, a rare blood disorder

M3 Acquires MirVracha LCC in Russia Launching Full-Scale Development of Physician Platform Business in Russia

M3, Inc. (Headquarters: Tokyo, Japan; CEO: Itaru Tanimura; URL: https://corporate.m3.com/; “M3” below) has announced the acquisition of MirVracha LCC (Headquarters: Moscow, Russia; CEO: Shotaro Yamamoto; “MirVracha” below), a website provider...

M3 (EU)

BHBIA logo

Listening to heads AND hearts in healthcare

We talk a lot about using emotions in healthcare communications, but not as much about the business intelligence(BI) behind it. Find out why it matters and why we are proud...

Cuttsy + Cuttsy

Logo showing that Cuttsy+Cuttsy are the 6th Independent Agency on the 2021 T40 listing

Does being an independent agency really matter?

With Cuttsy+Cuttsy ranked as #6 in the Independent Agencies listing from PM Live’s T40 Creative Healthcare Agencies 2021, Mathew Cutts reflects on what being ‘independent’ means to him.

Cuttsy + Cuttsy

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links